|Budget Amount *help
¥38,610,000 (Direct Cost: ¥29,700,000、Indirect Cost: ¥8,910,000)
Fiscal Year 2018: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2017: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2016: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2015: ¥7,800,000 (Direct Cost: ¥6,000,000、Indirect Cost: ¥1,800,000)
Fiscal Year 2014: ¥12,090,000 (Direct Cost: ¥9,300,000、Indirect Cost: ¥2,790,000)
|Outline of Final Research Achievements
To promote precision medicine of gastric carcinoma (GC), we studied pathological characteristics of four molecular subtypes of GC (EBV-positive GC, microsatellite instable GC, chromosome instable GC, and genomically stable GC), which were recently proposed by the international genome research group (TCGA).
The mechanisms by which cancer cells escape from the host immune system have been clarified in EBV-positive GC (viral copy numbers, expression and gene amplification of PD-L1, regulation of dendritic cells via exosomes and maintenance of cancer stemness were studied) and in microsatellite instable GC (intramucosal multi-clonality and lost expression of HLA class I).
Chromosome instable GC and genomically stable GC respectively include potentially distinct subgroups. We identified and characterized the following subgroups, fetal gastrointestinal epithelium-like GC in the former, and RHOA-mutated GC and CLDN18-ARHGAP fusion gene-positive GC in the latter subtype of GC.